Sector News

Russia suggests creating green corridor for pharmaceutical companies – deputy PM

March 27, 2018
Life sciences

Moscow has suggested to Tokyo that a green corridor be created for pharmaceutical companies, Russian Deputy Prime Minister Olga Golodets said ahead of a meeting with Japan’s Minister of Economy, Trade and Industry Hiroshige Seko on Saturday.

“We have suggested that the so-called green corridor be created for pharmaceutical companies, as we want to ease the access to the Russian market for Japanese companies,” she said, adding that talks on that matter have been held with Hitachi, Ltd.

The meeting also involves Russian Economic Development Minister Maksim Oreshkin.

Moscow and Tokyo have been have been boosting economic cooperation based on the Japanese prime minister’s eight-point plan. The document stipulates that Russia and Japan should strengthen relations in the energy sphere, small and medium-size business, the industrialization of Russia’s Far East, as well as expand exports.

Source: TASS

comments closed

Related News

November 26, 2023

ViCentra links insulin pump with Dexcom, Diabeloop tech to launch closed-loop diabetes system in Europe

Life sciences

Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.

November 26, 2023

Boehringer builds out cancer capabilities with $500M deal for bacteria-focused Swiss biotech

Life sciences

Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.

November 26, 2023

EuroAPI completes acquisition of BianoGMP

Life sciences

EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.

How can we help you?

We're easy to reach